Mengsi Yu1, Kainan Zhang1, Song Wang2, Li Xue1, Zhaoyun Chen1, Ning Feng1, Conghua Ning1, Lijuan Wang1, Jing Li3, Boke Zhang4, Changcheng Yang5, Zhaoxia Zhang1. 1. Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. 2. Department of Ophthalmology, General Hospital of Xinjiang Military Region, Urumqi, China. 3. Department of Internal Medicine, 958 Hospital of People's Liberation Army, Chongqing, China. 4. Clinical Laboratory Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China. 5. Department of Medical Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
Abstract
OBJECTIVE: SPHK1 and HAS2 have been reported to play important roles in tumorigenesis and development. However, their expression and prognostic value in pancreatic cancer (PC) remain unclear. This study is aimed at investigating the expression of SPHK1 and HAS2 on the prognosis of pancreatic cancer. MATERIALS AND METHODS: The expression of SPHK1 and HAS2 in pancreatic cancer tissues was analyzed through TCGA and GTEx databases and validated by qRT-PCR and Western blot in pancreatic cancer cell lines. χ 2 test was used to explore the correlation of the SPHK1 and HAS2 expressions with clinical characteristics. Kaplan-Meier survival analysis and ROC curve were used to evaluate the prognostic and diagnostic roles of SPHK1 and HAS2 in pancreatic cancer. Additionally, Spearman correlation analysis was applied to assess the correlation between the SPHK1 and HAS2 in pancreatic cancer. GO analysis and KEGG analysis were applied to explore the possible signaling pathway that SPHK1 and HAS2 coregulated genes mediated. RESULTS: The expression of SPHK1 and HAS2 was markedly upregulated in pancreatic cancer tissue and cell lines, respectively. Furthermore, there was a significant positive correlation between SPHK1 and HAS2 expressions. ROC curves showed that SPHK1 combine with HAS2 has good diagnostic value in pancreatic cancer patients with 85% sensitivity and 99.4% specificity. Kaplan-Meier analysis showed that increased expression of SPHK1 and HAS2 was significantly associated with short overall survival (OS) of pancreatic cancer patients. GO and KEGG results revealed that SPHK1 and HAS2 mainly involved cell proliferation and invasion mediated by extracellular matrix- (ECM-) receptor interaction, focal adhesion, and PI3K-AKT signaling pathways. CONCLUSIONS: Overexpression of SPHK1 and HAS2 could be important markers for the prognosis of pancreatic cancer.
OBJECTIVE: SPHK1 and HAS2 have been reported to play important roles in tumorigenesis and development. However, their expression and prognostic value in pancreatic cancer (PC) remain unclear. This study is aimed at investigating the expression of SPHK1 and HAS2 on the prognosis of pancreatic cancer. MATERIALS AND METHODS: The expression of SPHK1 and HAS2 in pancreatic cancer tissues was analyzed through TCGA and GTEx databases and validated by qRT-PCR and Western blot in pancreatic cancer cell lines. χ 2 test was used to explore the correlation of the SPHK1 and HAS2 expressions with clinical characteristics. Kaplan-Meier survival analysis and ROC curve were used to evaluate the prognostic and diagnostic roles of SPHK1 and HAS2 in pancreatic cancer. Additionally, Spearman correlation analysis was applied to assess the correlation between the SPHK1 and HAS2 in pancreatic cancer. GO analysis and KEGG analysis were applied to explore the possible signaling pathway that SPHK1 and HAS2 coregulated genes mediated. RESULTS: The expression of SPHK1 and HAS2 was markedly upregulated in pancreatic cancer tissue and cell lines, respectively. Furthermore, there was a significant positive correlation between SPHK1 and HAS2 expressions. ROC curves showed that SPHK1 combine with HAS2 has good diagnostic value in pancreatic cancer patients with 85% sensitivity and 99.4% specificity. Kaplan-Meier analysis showed that increased expression of SPHK1 and HAS2 was significantly associated with short overall survival (OS) of pancreatic cancer patients. GO and KEGG results revealed that SPHK1 and HAS2 mainly involved cell proliferation and invasion mediated by extracellular matrix- (ECM-) receptor interaction, focal adhesion, and PI3K-AKT signaling pathways. CONCLUSIONS: Overexpression of SPHK1 and HAS2 could be important markers for the prognosis of pancreatic cancer.
Authors: Päivi Auvinen; Kirsi Rilla; Ritva Tumelius; Markku Tammi; Reijo Sironen; Ylermi Soini; Veli-Matti Kosma; Arto Mannermaa; Jukka Viikari; Raija Tammi Journal: Breast Cancer Res Treat Date: 2013-12-14 Impact factor: 4.872
Authors: Yoon Mee Yang; Mazen Noureddin; Cheng Liu; Koichiro Ohashi; So Yeon Kim; Divya Ramnath; Elizabeth E Powell; Matthew J Sweet; Yoon Seok Roh; I-Fang Hsin; Nan Deng; Zhenqiu Liu; Jiurong Liang; Edward Mena; Daniel Shouhed; Robert F Schwabe; Dianhua Jiang; Shelly C Lu; Paul W Noble; Ekihiro Seki Journal: Sci Transl Med Date: 2019-06-12 Impact factor: 17.956
Authors: Mathias Uhlen; Cheng Zhang; Sunjae Lee; Evelina Sjöstedt; Linn Fagerberg; Gholamreza Bidkhori; Rui Benfeitas; Muhammad Arif; Zhengtao Liu; Fredrik Edfors; Kemal Sanli; Kalle von Feilitzen; Per Oksvold; Emma Lundberg; Sophia Hober; Peter Nilsson; Johanna Mattsson; Jochen M Schwenk; Hans Brunnström; Bengt Glimelius; Tobias Sjöblom; Per-Henrik Edqvist; Dijana Djureinovic; Patrick Micke; Cecilia Lindskog; Adil Mardinoglu; Fredrik Ponten Journal: Science Date: 2017-08-18 Impact factor: 47.728
Authors: Jette Riecks; Arianna Parnigoni; Balázs Győrffy; Ludwig Kiesel; Alberto Passi; Davide Vigetti; Martin Götte Journal: J Cancer Res Clin Oncol Date: 2022-06-29 Impact factor: 4.322
Authors: Vijayasarathy Ketavarapu; Vishnubhotla Ravikanth; Mitnala Sasikala; G V Rao; Ch Venkataramana Devi; Prabhakar Sripadi; Murali Satyanarayana Bethu; Ramars Amanchy; H V V Murthy; Stephen J Pandol; D Nageshwar Reddy Journal: BMC Cancer Date: 2022-07-19 Impact factor: 4.638